Dual Drug Nanoformulations for Non-Small Cell Lung Cancer Therapeutics: A Systematic Review

Le résumé fourni par la source

Background Lung cancer is the most common cause of cancer mortality around the world, and non-small cell lung cancer (NSCLC) represents 80% of the lung cancer subtypes. Various factors, including gene alterations and changes in an individual's lifestyle, are potential causes of the disease. Many FDA-approved drugs have been used to treat the disease, but their success rate is still not halfway to the mark. Nano-based delivery provides better biocompatibility and targeted delivery without compromising the effectiveness of the drugs. Objectives The objectives of this systematic literature review are to find the current epidemiology and status of lung cancer TNM classification. The molecular targets of NSCLC and how dual drug nanoformulations can manage NSCLC. Methods We shortlisted articles from the Google Scholar literature database based on relevant filters and inclusion and exclusion criteria. Further screening was performed, which resulted in papers being excluded because they poorly aligned with NSCLC or dual drug nanoformulation. Articles addressing epidemiology, TNM classification, molecular targets, and dual drug nanoformulations were included. Results We have summarized the studies done on dual drug nanoformulation developments. We primarily discussed epidemiology and the alterations that cause the onset of the disease. Next, we discussed the types of nanoparticles used in targeted delivery and dual drug nanoformulations. Conclusion Dual drug nanoformulations would give a synergistic anti-cancerous effect, which tends to give a better result on the disease and reduce individual drug-related toxicity, suppressing multi-drug resistance through different mechanisms of action and reducing the dose of each agent. Preclinical trials, including in silico , in vitro , and in vivo studies on mouse models, have shown them to be a better alternative to conventional methods. Given their accessibility and therapeutic benefits, these nanoformulations offer a promising approach to managing NSCLC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.